Request Trial
8 July 2025NewsBiotechHa Kung Wong, Venable | Karen Martin, Ipsen | Nitin Virmalwar, Stoke Therapeutics | Jennifer Moitoso, Biogen

WATCH: Mastering the art of IP transactions—due diligence, valuation, and deal-making

LSPN brings together experts from Venable, Ipsen, Stoke Therapeutics, and Biogen to analyse best practices for IP transactions, from due diligence and valuation to structuring deals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Biotech
Regeneron and Amgen call a truce on two Eylea biosimilar patents
28 October 2026   Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.
Biotech
Amgen hit with lawsuit over its proposed Opdivo biosimilar
16 September 2026   BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.
Biotech
Pfizer strikes $10.5 billion oncology deal with Chinese biotech
4 June 2026   The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.


Editor's picks

WATCH: Medmix global IP head on building business-focused IP teams
In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026

Editor's picks

In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026

More features

UK unveils £1bn sector investment push after recent setbacks
Justice Joanna Smith appointed to interim High Court role as Sir Colin Birss replaces Sir Geoffrey Vos
Oura targets Ultrahuman’s redesigned smart ring following import ban
Weil collapse leaves IP talent facing uncertain future after major expansion
Meril turns the tables on Edwards with European patent revocation
Latham lands pharma and tech expert in London
Regeneron and Amgen call a truce on two Eylea biosimilar patents
HeartFlow targets AI cardiac imaging rival over patents and trade secrets